Remedi to List on KOSDAQ on July 13 Amid 1,701x Subscription Ratio

On July 13, South Korean medical device manufacturer Remedi will debut on KOSDAQ after securing a final offering price of 21,500 won at the upper end of guidance, according to local IPO calendar data. The company received a subscription ratio of 1,701 to 1 from retail investors, with institutional demand also concentrated at the upper end of pricing range, signaling strong market interest.

HLG Genomics, a pharmaceutical subsidiary of Halim Pharmaceutical, will conduct subscription for the same week on July 13-14, with its offering price also confirmed at 21,500 won, the upper limit of its guidance range. The company plans to raise 55.1 billion won through the public offering.